How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

Sun Pharmaceutical Industries Q2 Results Live : Sun Pharmaceutical Industries declared its Q2 results on October 28, 2024, showcasing a robust financial performance. The company reported a topline ...

Sun Pharmaceutical Industries slipped 4.30% to 1,778.85 after the US District Court of New Jersey has decided to grant a preliminary injunction delaying the launch of Leqselvi (Baldness treatment) in ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Sun Pharmaceutical Industries has reported a notable 28% increase in its consolidated net profit, amounting to Rs 3,040 crore ...

Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of ...

Sun Pharmaceutical Industries reported a 28% rise in net profit, reaching Rs 3,040 crore for the September quarter, driven by ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.18% to 1,849.05 Indian rupees Thursday, on what proved to be an all-around rough trading session for the stock market, with the ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

Sun Pharmaceuticals , India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on ...